[10] Engstrom LD, et al., (2023). MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov, doi: 10.1158/2159-8290.CD-23-0669. [1...
一种选择性结合并稳定催化失活的PRMT5/MTA复合物的小分子被预测将进一步抑制MTAP缺失肿瘤中残留的PRMT5活性，并可能代表一种针对这些癌症患者的合成致死精准药物。近期，来自美国Mirati Therapeutics的Peter Olson博士团队在 Cancer Discovery 杂志上发表文章MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits ...
近日,来自美国Amgen公司的Paul E. Hughes博士携团队在Cancer Discovery杂志上发表文章AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients With MTAP-Deleted Cancers。本...
4, Debomita Bhattacharya et al; Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to NonNucleoside Analogues.J. Med. Chem. 2022, 65, 1662−1684.5, Matthew A. Marx et al; Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor ...
3, TPS3167: design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. 4, Debomita Bhattacharya et al; Fascinating Transformation of SAM-Competiti...
2.MatthewA.Marxetal;Fragment-BasedDiscoveryofMRTX1719,aSyntheticLethalInhibitorofthePRMT5•MTAComplexfortheTreatmentofMTAPDeletedCancers.J.Med.Chem.2022,65,1749−1766. 3.AmgenBusinessReviewMeeting.RetrievedFebruary8,2022,fromhttps://investors.amgen.com/static-files/6d823d7d-2fd1-405a-8c0e-22aa...
[1]Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors 注:以上资讯来源于网络,由医伴旅整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品...
[5] https://clinicaltrials.gov/ct2/home; [6] 医药魔方数据库; [7]AACR-NCI-EORTC 2021: MRTX1719: A First-in-class MTA-cooperative PRMT5 Inhibitor that Selectively Elicits Antitumor Activity in MTAP/CDKN2A Deleted Cancer Models; ...
5. AACR-NCI-EORTC 2021:MRTX1719: A First-in-class MTA-cooperative PRMT5 Inhibitor that Selectively Elicits Antitumor Activity in MTAP/CDKN2A Deleted Cancer Models. 6.Bedford, M. T.; Clarke, S. G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 2009, 33 (1), ...
5. AACR-NCI-EORTC 2021:MRTX1719: A First-in-class MTA-cooperative PRMT5 Inhibitor that Selectively Elicits Antitumor Activity in MTAP/CDKN2A Deleted Cancer Models. 6.Bedford, M. T.; Clarke, S. G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 2009, 33 (1),...